United States: FDA Approves Sandoz Denosumab Biosimilars - Goodwin Procter LLP
On March 5, Sandoz announced that the FDA approved its denosumab biosimilars, WYOST and JUBBONTI, as interchangeable with Amgen's XGEVA and PROLIA.
Full Article
United States: FDA Approves Sandoz Denosumab Biosimilars - Goodwin Procter LLP
Mondaq
0 shares
1 views
You might like
Related news coverage
United States: Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP
Mondaq
On March 7, Fresenius Kabi announced that the FDA has approved its tocilizumab biosimilar, TYENNE (tocilizumab-aazg) for..
-
United States: FDA's Laboratory Developed Test (LDT) Final Rule Under OIRA Review; Subcommittee On Health To Hold Hearing On Regulation Of Diagnostic Tests - Goodwin Procter LLP
Mondaq
-
United States: Teva And Alvotech's Adalimumab Biosimilar Receives Interchangeable Status At FDA - Goodwin Procter LLP
Mondaq
-
United States: Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK In Lupus Nephritis - Goodwin Procter LLP
Mondaq
-
United States: FDA Approves First Cellular Therapy For Treatment Of Unresectable Or Metastatic Melanoma - Goodwin Procter LLP
Mondaq